Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants - Test2 - elhamkhani - TriplyDB

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

http://www.wikidata.org/entity/Q24810573

about

Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment Molecular biology of lung cancer The role of Src in solid tumors Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations Somatic DNA mutation analysis in targeted therapy of solid tumours Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer The Evolution of Therapies in Non-Small Cell Lung Cancer A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives Ligand-Independent EGFR Signaling Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors Tank binding kinase 1 is a centrosome-associated kinase necessary for microtubule dynamics and mitosis.Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor Molecular pathology of lung cancer: key to personalized medicine.Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.Activating mutations in ALK provide a therapeutic target in neuroblastoma.Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab.In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain Epidermal growth factor receptor in non-small cell lung cancer A kinase cascade leading to Rab11-FIP5 controls transcytosis of the polymeric immunoglobulin receptor Constitutive activation of epidermal growth factor receptor promotes tumorigenesis of Cr(VI)-transformed cells through decreased reactive oxygen species and apoptosis resistance development TERT Polymorphism rs2736100-C Is Associated with EGFR Mutation-Positive Non-Small Cell Lung Cancer Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expression Detection of mutations in EGFR in circulating lung-cancer cells The Rak/Frk tyrosine kinase associates with and internalizes the epidermal growth factor receptor.Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.Capturing the time-varying drivers of an epidemic using stochastic dynamical systems.Inhibition of EGFR signaling: all mutations are not created equal.Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations.

P2860

Q24309071-6761A25A-CD81-405C-BD29-5C883C49669B Q24606677-1CA08B0C-FC67-4E25-8486-7A34E9DCC97B Q24616659-DB06F269-BD21-4857-B18F-847302E365ED Q24648133-26AEB2D6-CE75-4DD2-960D-12C9AC3F58F1 Q24649549-5CC9B092-2F27-4421-AC65-A91CF82B64EB Q24649935-BEF42D17-7648-447F-8490-9E169C287280 Q24685474-F5D072C9-A72E-4FA5-9C0E-5EEFEC245DBB Q26744339-AA959491-DC01-46FE-9093-41DC318BAFE4 Q26770324-CAC3B431-76CD-46CB-9E8E-57C82D3B846D Q26781810-DDEA3045-0869-4CF3-8236-C61A80A33C34 Q26786932-CC931027-5E6F-4401-BAC6-9F152CD7E198 Q26797297-174185C2-88D5-4FA9-A8FC-74112C2AA2B3 Q26797495-C5D8040E-409A-4F3B-A831-FF53382538D2 Q27014117-FE23DAB9-0673-4BE0-9C10-47FB8EBE1BA4 Q27021738-99F102C6-4F61-4464-AB8E-CAF01EE73556 Q27302811-35822004-75A2-42AF-BA1B-F31131200441 Q27305848-B1504CB0-600F-475D-B161-C77C276FD6B7 Q27310990-6751F588-FA53-4D0C-9AC3-8538AA3065AB Q27342059-C2D3255B-D4F4-4FC7-8155-9CF4AFA9F38C Q27644014-7AEF9CA4-1353-429B-9D95-E20273A5E65C Q27677383-B48231AD-3543-41F7-9431-CF0CA61FDFF2 Q27691299-3116E7B9-9C31-4905-86F4-625679096AF1 Q27851396-B92BEEC4-644A-4428-9EEB-A51F4489E8E2 Q27851452-BFB04CDB-6E50-4173-B3A5-2F49041E570E Q27853014-64E03364-8CE1-4569-9E61-4DD1CEBF3789 Q27853236-60547670-128A-40B1-B0E2-7F5FDB17A049 Q27865182-2DE542FF-4FA7-4FE6-A96D-8142FAE3804E Q28088636-C1A8932A-C2DF-479F-A00F-BDDAA0488BB3 Q28297272-CF79321D-AB4B-4ADC-B710-4D3BFA707515 Q28386290-EB758F9C-29C5-459E-8077-0CCBDAB79601 Q28393844-A5D88352-57D4-43F9-B15C-3E59417B2632 Q28484612-98F09344-53F2-45FA-AD66-573D6CD5113B Q29615033-39CAE63B-5C0C-4380-9285-5F553EFEC47F Q30009944-CC0B3606-3998-4AE5-9378-FDC78A67D96F Q30014823-25F4D558-C7AB-4E6E-9B85-F16923E39562 Q30374663-5D3B4F80-26C7-4887-920C-0BB631C832F3 Q30397503-48792C57-3FC1-4371-A03A-0C4066D884F0 Q30425559-C18D70E3-FF46-4A19-9127-AE17071DD5FE Q33227206-C4299E89-B3C0-4522-8902-2931CD0AF123 Q33306709-ED85D4E7-877C-461E-861B-A526A5923B66

P2860

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

http://www.wikidata.org/entity/Q24810573

description

2005 nî lūn-bûn

@nan

2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

@ast

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

@en

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

@nl

type

label

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

@ast

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

@en

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

@nl

prefLabel

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

@ast

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

@en

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

@nl

P1433

Q24810573-2BACDA4E-2B6B-40E5-A2CF-BFA6E86194BA

P1476

Q24810573-0B2DA087-E36D-4F36-8B47-8A45EF69A320

P2093

Q24810573-3155A224-89BE-4DCC-8E37-497F00520527

Q24810573-3B062D49-95F3-4C3C-81BF-A72232B6A731

Q24810573-55A5B5FF-0571-4664-A1FC-B80A52F392F2

Q24810573-6806CE44-11DA-4528-A8B6-F752D6DD4ED9

Q24810573-846B1EDA-8F0C-437B-AC9C-977552B29EB5

Q24810573-A660CDF6-C0B2-4E0D-9841-DCDF7F2DC892

Q24810573-CB921B36-0EB6-44C5-901C-576B8C3860F4

Q24810573-DD2DC895-3332-4D37-A0F5-DEE8BE26C7FF

P2860

Q24810573-069584DD-B30E-4F07-B96F-ED613DEE2E5A

Q24810573-07DED040-8F79-4DC1-A6CA-E07F66849A1E

Q24810573-09EC9F50-975A-4C4B-8150-A84214B59E97

Q24810573-18A57545-D088-40CD-9ACF-2B77ED58D479

Q24810573-210E4D38-E6E7-41C3-B82D-78EDF0A376A6

Q24810573-222C94D0-AD08-4B7F-926E-910D9DD0C266

Q24810573-2402F0A2-E5C9-4454-870A-69259A420E93

Q24810573-281091E3-A88B-40A9-99E4-BD6647115125

Q24810573-348D0ADD-231F-4112-AAF0-EABDE90628D4

Q24810573-46C33B1C-3A12-40C3-9625-F7D5DFF711C1

P304

Q24810573-3ADE9ED9-5698-461A-B1FD-493DD6A99658

P31

Q24810573-CFF8109D-C76A-4086-81DC-FAE34F9E1D2E

P3181

Q24810573-DE3E6498-BA63-46DA-9EB1-8823C2C8571A

P356

Q24810573-330820D6-EEFC-4680-9292-CFB4DAD36844

P407

Q24810573-A545E8C2-775A-4445-B8A5-0A3A2F1C0E02

P433

Q24810573-C27A8F32-DADB-4CEB-9364-5ECBB7FE8FB6

P478

Q24810573-712C5AB7-9974-44C4-B675-86558BC58370

P50

Q24810573-0BF0A6E0-6812-45EE-9352-C675054C3BA4

Q24810573-56341AA0-F5AA-41A3-954E-F0F1660F964E

Q24810573-E3F8310A-1F18-41AB-AE7E-6F813F1E8993

P577

Q24810573-537F5E0D-FBB2-4F5E-B6FF-7EFF7751BA07

P5875

Q24810573-405A1BAF-F75D-4FD9-B3C8-CCAD9C0E8863

P698

Q24810573-95EE35CD-3492-4BF9-B590-98A551EF86E2

P932

Q24810573-62EAA3A1-5395-4806-9C02-28E0C826ED6D

P3181

P356

JOURNAL.PMED.0020313

P1433

P1476

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.

@en

P2093

David A Frank

http://www.w3.org/2001/XMLSchema#string

James V Alvarez

http://www.w3.org/2001/XMLSchema#string

Mauro Zappaterra

http://www.w3.org/2001/XMLSchema#string

Sara E Bulmer

http://www.w3.org/2001/XMLSchema#string

Tzu-Hsiu Chen

http://www.w3.org/2001/XMLSchema#string

Whei Feng

http://www.w3.org/2001/XMLSchema#string

William C Hahn

http://www.w3.org/2001/XMLSchema#string

William R Sellers

http://www.w3.org/2001/XMLSchema#string

P2860

Tyrosines 1148 and 1173 of activated human epidermal growth factor receptors are binding sites of Shc in intact cells

A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Creation of human tumour cells with defined genetic elements

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling

P304

e313

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

355072

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PMED.0020313

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Matthew Meyerson

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7576277

http://www.w3.org/2001/XMLSchema#string

P698

16187797

http://www.w3.org/2001/XMLSchema#string

P932

1240052

http://www.w3.org/2001/XMLSchema#string